Preferred Label : BCMA-CD19 Compound CAR T Cells;
NCIt synonyms : BCMA-CD19 cCAR T Cells; BCMA-CD19 cCAR T-cells;
NCIt definition : A preparation of T-lymphocytes transduced with a lentiviral vector expressing a compound
chimeric antigen receptor (cCAR) containing two distinct units of CARs, one specific
for the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis
factor receptor superfamily member 17; TNFRSF17) and one specific for the TAA CD19,
with potential immunomodulating and antineoplastic activities. Upon administration,
the BCMA-CD19 cCAR T cells specifically and simultaneously target and bind to tumor
cells expressing BCMA and/or CD19. This induces selective toxicity in tumor cells
that express BCMA and/or CD19. BCMA, a tumor-specific antigen and a receptor for both
a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a
member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key
role in the survival of B-lymphocytes and plasma cells. BCMA is found on the surfaces
of B-cells and is overexpressed on malignant plasma cells. CD19 is a B-cell-specific
cell surface antigen overexpressed in B-cell lineage malignancies. Targeting two different
antigens may improve coverage and protect against antigen escape and relapse as it
is less likely for tumor cells to lose both antigens.;
NCI Metathesaurus CUI : CL1411933;
Origin ID : C174412;
UMLS CUI : C5420764;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
- has_target
